Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Cancer screening blood test Photo: Jacqueline Larma / AP

A spate of recent studies on liquid biopsies for cancer suggests researchers are making progress toward their ultimate goal of non-invasive diagnostics for evaluating how well a cancer treatment is working and early detection of the disease. However, the tests remain in early stages of development and still face doubts from some experts as to whether they can overcome issues like high rates of false negatives or positives.

"This is the wave of the future...The question is: How do we do it better? There are lots of directions it can move in," Eric Topol, genomics scientist and director of The Scripps Research Institute not involved in these studies, told Axios.

Early cancer detection study: A Johns Hopkins team announced Wednesday they have developed a blood test that spots tiny bits of DNA in the blood and, in the study, used them to accurately identified more than half of 138 people with relatively early stages of colorectal, breast, lung, and ovarian cancers.

Other recent research includes:

Johns Hopkins' study: The team said they developed a new approach that can distinguish between the DNA shed from tumors and other altered DNA that occurs naturally in humans but is often mistaken for cancer biomarkers. The technique uses "deep sequencing," which reads 30,000 times each chemical code in more than 80,930 base pairs of DNA fragments.

They used it to find and test DNA in the blood of 44 healthy patients and 200 cancer patients, and were able to detect an average of 62% of stage I and II cancers in the participants. Specifically, they found stage I and II cancers in: 71% of colorectal patients, 59% of breast cancer patients, 59% of lung cancer patients, and 68% of ovarian cancer patients. While it is difficult to find ovarian cancer patients in stage I or II (it tends to be found in stage III or beyond), the team said it canvassed various institutions to obtain the samples.

"To our knowledge this is the first reported study where such an approach has used these steps to achieve direct detection of early stage cancers," study author Jillian Phallen told Axios via email.

And, importantly: When the researchers analyzed the blood of the 44 healthy volunteers, their tests showed very little false positives (roughly one false positive per 3.3 million letters of DNA sequenced.)

Another perspective: Theodora Ross, an oncologist at the UT Southwestern Medical Center who did not participate in any of these studies, told Axios it is too early to believe the hype surrounding liquid biopsies. She says "theoretically" the tests could be a great tool that would allow doctors to avoid tissue biopsies and to detect cancers earlier but there has not yet been any large verification studies that prove these tests will work.

Yes, but: Ross said the test developed at Johns Hopkins appears to be more sensitive than some other liquid biopsies, which was confirmed by the lower error rate in testing the healthy subjects. If this could be validated by larger studies, Ross said, this would help ease one of her main concerns about liquid biopsies:

  • the prevalence of false positives (which may cause the patient to unnecessarily undergo severe radiation and chemo treatments or simply suffer with the knowledge of an incurable cancer longer)
  • false negatives (which may allow the cancer to grow undetected).

Going forward: Topol agreed validation studies are needed for these studies, with the hope that eventually scientists will achieve more accurate results with lower costs. "There is no perfect study...but this is a step in the right direction," he said.

Go deeper

Capitol repairs, security top $30M since Jan. 6 attacks

Photo: Bill Clark/CQ-Roll Call, Inc via Getty Images

The Architect of the Capitol Brett Blanton on Wednesday said that repairs and security expenses related to the Jan. 6 insurrection have already cost more than $30 million.

The state of play: Congressional appropriations committees have allocated the $30 million for repairs and perimeter fencing around the Capitol building through March 31, per NPR.

Updated 3 hours ago - Politics & Policy

White House stands by imperiled Tanden nomination after Senate panel postpones hearing

Neera Tanden. Photo: Anna Moneymaker/The New York Times/Bloomberg via Getty Images

The Senate Homeland Security Committee is postponing a confirmation hearing scheduled Wednesday for Neera Tanden, Axios has learned, a potential death knell for President Biden's nominee to lead the Office of Management and Budget.

The latest: Asked Wednesday afternoon whether Tanden has offered to withdraw her nomination, Psaki told reporters, "That’s not the stage we’re in." She noted that it's a "numbers game" and a "matter of getting one Republican" to support the nomination.

Acting Capitol Police chief: Officers were unsure of lethal force rules on Jan. 6

Photo: Chip Somodevilla/Getty Images

Acting U.S. Capitol Police Chief Yogananda Pittman wrote in prepared remarks for a House hearing on Thursday that officers in her department were "unsure of when to use lethal force" during the Jan. 6 insurrection.

Why it matters: Capitol Police did deploy lethal force on Jan. 6 — shooting and killing 35-year-old Ashli Babbit — but have faced questions over why officers appeared to be less forceful against pro-Trump rioters than participants in previous demonstrations, including those over Black Lives Matter and now-Supreme Court Justice Brett Kavanaugh.